{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:29:30Z","timestamp":1789039770597,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["No. CSTB2024NSCQ-MSX1266"],"award-info":[{"award-number":["No. CSTB2024NSCQ-MSX1266"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07529-5","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T01:53:55Z","timestamp":1764813235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Pusheng","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8948-7297","authenticated-orcid":false,"given":"Youlin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"7529_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7529_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primer. 2021;7:9.","journal-title":"Nat Rev Dis Primer"},{"key":"7529_CR3","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.23.00723","volume":"41","author":"J Wala","year":"2023","unstructured":"Wala J, Nguyen P, Pomerantz M. Early treatment intensification in metastatic Hormone-Sensitive prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:3584\u201390.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7529_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.18.01279","volume":"37","author":"S Halabi","year":"2019","unstructured":"Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, et al. Overall survival of black and white men with metastatic Castration-Resistant prostate cancer treated with docetaxel. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:403\u201310.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7529_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2021.08.033","volume":"523","author":"V Ruiz de Porras","year":"2021","unstructured":"Ruiz de Porras V, Font A, Aytes A. Chemotherapy in metastatic castration-resistant prostate cancer: current scenario and future perspectives. Cancer Lett. 2021;523:162\u20139.","journal-title":"Cancer Lett"},{"key":"7529_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-arplant-102820-093218","volume":"74","author":"T Bieluszewski","year":"2023","unstructured":"Bieluszewski T, Prakash S, Roul\u00e9 T, Wagner D. The role and activity of SWI\/SNF chromatin remodelers. Annu Rev Plant Biol. 2023;74:139\u201363.","journal-title":"Annu Rev Plant Biol"},{"key":"7529_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41576-023-00666-x","volume":"25","author":"S Gourisankar","year":"2024","unstructured":"Gourisankar S, Krokhotin A, Wenderski W, Crabtree GR. Context-specific functions of chromatin remodellers in development and disease. Nat Rev Genet. 2024;25:340\u201361.","journal-title":"Nat Rev Genet"},{"key":"7529_CR8","first-page":"167","volume":"44","author":"S Clune","year":"2025","unstructured":"Clune S, Awolade P, Esquer H, Zhou Q, LaBarbera DV. CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential. J Exp Clin Cancer Res CR. 2025;44:167.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"7529_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-021-00269-w","volume":"9","author":"X Xiong","year":"2021","unstructured":"Xiong X, Lai X, Li A, Liu Z, Ma N. Diversity roles of CHD1L in normal cell function and tumorigenesis. Biomark Res. 2021;9:16.","journal-title":"Biomark Res"},{"key":"7529_CR10","doi-asserted-by":"publisher","first-page":"1017148","DOI":"10.3389\/fmolb.2023.1017148","volume":"10","author":"MA Soltan","year":"2023","unstructured":"Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, et al. A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers. Front Mol Biosci. 2023;10:1017148.","journal-title":"Front Mol Biosci"},{"key":"7529_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13048-024-01582-2","volume":"18","author":"K Qiao","year":"2025","unstructured":"Qiao K, Guan Y, Xing W. Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1. J Ovarian Res. 2025;18:38.","journal-title":"J Ovarian Res"},{"key":"7529_CR12","doi-asserted-by":"publisher","first-page":"eabb8626","DOI":"10.1126\/sciadv.abb8626","volume":"6","author":"S Juh\u00e1sz","year":"2020","unstructured":"Juh\u00e1sz S, Smith R, Schauer T, Spekhardt D, Mamar H, Zentout S, et al. The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment. Sci Adv. 2020;6:eabb8626.","journal-title":"Sci Adv"},{"key":"7529_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13578-023-01113-4","volume":"13","author":"H He","year":"2023","unstructured":"He H, Li J, Wang W, Cheng J, Zhou J, Li Q, et al. The SIRT7-mediated deacetylation of CHD1L amplifies HIF-2\u03b1-dependent signal that drives renal cell carcinoma progression and Sunitinib resistance. Cell Biosci. 2023;13:166.","journal-title":"Cell Biosci"},{"key":"7529_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbrc.2020.12.109","volume":"554","author":"G-T Fan","year":"2021","unstructured":"Fan G-T, Ling Z-H, He Z-W, Wu S-J, Zhou G-X. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma. Biochem Biophys Res Commun. 2021;554:214\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"7529_CR15","doi-asserted-by":"publisher","first-page":"116037","DOI":"10.1016\/j.biopha.2023.116037","volume":"170","author":"S Clune","year":"2024","unstructured":"Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, et al. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomed Pharmacother Biomedecine Pharmacother. 2024;170:116037.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"7529_CR16","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1021\/acs.jmedchem.1c01778","volume":"65","author":"BJ Prigaro","year":"2022","unstructured":"Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai X-H, et al. Design, Synthesis, and biological evaluation of the first inhibitors of oncogenic CHD1L. J Med Chem. 2022;65:3943\u201361.","journal-title":"J Med Chem"},{"key":"7529_CR17","doi-asserted-by":"publisher","first-page":"13160","DOI":"10.3390\/ijms252313160","volume":"25","author":"R Sala","year":"2024","unstructured":"Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, et al. CHD1L inhibitor OTI-611 synergizes with chemotherapy to enhance antitumor efficacy and prolong survival in colorectal cancer mouse models. Int J Mol Sci. 2024;25:13160.","journal-title":"Int J Mol Sci"},{"key":"7529_CR18","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.3390\/ijms25168590","volume":"25","author":"R Sala","year":"2024","unstructured":"Sala R, Esquer H, Kellett T, Kearns JT, Awolade P, Zhou Q, et al. CHD1L regulates cell survival in breast cancer and its Inhibition by OTI-611 impedes the DNA damage response and induces parthanatos. Int J Mol Sci. 2024;25:8590.","journal-title":"Int J Mol Sci"},{"key":"7529_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cells14050318","volume":"14","author":"H Esquer","year":"2025","unstructured":"Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 reprograms chemotherapy and targeted Therapy-Induced cell cycle arrest and suppresses proliferation to produce synergistic antitumor effects in breast and colorectal cancer. Cells. 2025;14:318.","journal-title":"Cells"},{"key":"7529_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","volume":"17","author":"Y Liu","year":"2018","unstructured":"Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, et al. Critical role of FOXO3a in carcinogenesis. Mol Cancer. 2018;17:104.","journal-title":"Mol Cancer"},{"key":"7529_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41580-023-00649-0","volume":"25","author":"MJ Rodriguez-Colman","year":"2024","unstructured":"Rodriguez-Colman MJ, Dansen TB, Burgering BMT. FOXO transcription factors as mediators of stress adaptation. Nat Rev Mol Cell Biol. 2024;25:46\u201364.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7529_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.semcancer.2017.07.007","volume":"50","author":"CG Kim","year":"2018","unstructured":"Kim CG, Lee H, Gupta N, Ramachandran S, Kaushik I, Srivastava S, et al. Role of forkhead box class O proteins in cancer progression and metastasis. Semin Cancer Biol. 2018;50:142\u201351.","journal-title":"Semin Cancer Biol"},{"key":"7529_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1084\/jem.20060353","volume":"203","author":"H You","year":"2006","unstructured":"You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, et al. FOXO3a-dependent regulation of Puma in response to cytokine\/growth factor withdrawal. J Exp Med. 2006;203:1657\u201363.","journal-title":"J Exp Med"},{"key":"7529_CR24","doi-asserted-by":"publisher","first-page":"9498","DOI":"10.1093\/nar\/gkr638","volume":"39","author":"S Amente","year":"2011","unstructured":"Amente S, Zhang J, Lavadera ML, Lania L, Avvedimento EV, Majello B. Myc and PI3K\/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression. Nucleic Acids Res. 2011;39:9498\u2013507.","journal-title":"Nucleic Acids Res"},{"key":"7529_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41419-025-07378-6","volume":"16","author":"T Oyama","year":"2025","unstructured":"Oyama T, Brashears CB, Rathore R, Benect-Hamilton H, Caldwell KE, Dirckx N, et al. PHGDH Inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma. Cell Death Dis. 2025;16:89.","journal-title":"Cell Death Dis"},{"key":"7529_CR26","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1038\/onc.2013.384","volume":"33","author":"P Dey","year":"2014","unstructured":"Dey P, Str\u00f6m A, Gustafsson J-\u00c5. Estrogen receptor \u03b2 upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. 2014;33:4213\u201325.","journal-title":"Oncogene"},{"key":"7529_CR27","doi-asserted-by":"publisher","first-page":"116011","DOI":"10.1016\/j.bcp.2023.116011","volume":"220","author":"X-Y Meng","year":"2024","unstructured":"Meng X-Y, Wang K-J, Ye S-Z, Chen J-F, Chen Z-Y, Zhang Z-Y, et al. Sinularin stabilizes FOXO3 protein to trigger prostate cancer cell intrinsic apoptosis. Biochem Pharmacol. 2024;220:116011.","journal-title":"Biochem Pharmacol"},{"key":"7529_CR28","doi-asserted-by":"publisher","first-page":"e20201974","DOI":"10.1084\/jem.20201974","volume":"218","author":"Z Chen","year":"2021","unstructured":"Chen Z, Huo D, Li L, Liu Z, Li Z, Xu S, et al. Nuclear DEK preserves hematopoietic stem cells potential via NCoR1\/HDAC3-Akt1\/2-mTOR axis. J Exp Med. 2021;218:e20201974.","journal-title":"J Exp Med"},{"key":"7529_CR29","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216\u201321.","journal-title":"Nucleic Acids Res"},{"key":"7529_CR30","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"7529_CR31","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"7529_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor Pathway-Independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474\u2013e4896.","journal-title":"Cancer Cell"},{"key":"7529_CR33","doi-asserted-by":"publisher","first-page":"12530","DOI":"10.3390\/ijms222212530","volume":"22","author":"DE Habrowska-G\u00f3rczy\u0144ska","year":"2021","unstructured":"Habrowska-G\u00f3rczy\u0144ska DE, Kozie\u0142 MJ, Kowalska K, Piastowska-Ciesielska AW. FOXO3a and its regulators in prostate cancer. Int J Mol Sci. 2021;22:12530.","journal-title":"Int J Mol Sci"},{"key":"7529_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.biopha.2016.11.120","volume":"88","author":"X Qiu","year":"2017","unstructured":"Qiu X, Dou Y. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother Biomedecine Pharmacother. 2017;88:430\u20135.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"7529_CR35","first-page":"1613","volume":"34","author":"S Shukla","year":"2009","unstructured":"Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol. 2009;34:1613\u201320.","journal-title":"Int J Oncol"},{"key":"7529_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-020-0088-2","volume":"20","author":"G Calissi","year":"2021","unstructured":"Calissi G, Lam EW-F, Link W. Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021;20:21\u201338.","journal-title":"Nat Rev Drug Discov"},{"key":"7529_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.tips.2022.09.010","volume":"43","author":"A Orea-Soufi","year":"2022","unstructured":"Orea-Soufi A, Paik J, Bragan\u00e7a J, Donlon TA, Willcox BJ, Link W. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci. 2022;43:1070\u201384.","journal-title":"Trends Pharmacol Sci"},{"key":"7529_CR38","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.arr.2022.101621","volume":"78","author":"RL McIntyre","year":"2022","unstructured":"McIntyre RL, Liu YJ, Hu M, Morris BJ, Willcox BJ, Donlon TA, et al. Pharmaceutical and nutraceutical activation of FOXO3 for healthy longevity. Ageing Res Rev. 2022;78:101621.","journal-title":"Ageing Res Rev"},{"key":"7529_CR39","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin M-E, Kungel TM, et al. Systemic therapy in patients with metastatic Castration-Resistant prostate cancer: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43:2311\u201334.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7529_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, et al. Intensification approaches and treatment sequencing in metastatic Castration-resistant prostate cancer: A systematic review. Eur Urol. 2025;87:29\u201346.","journal-title":"Eur Urol"},{"key":"7529_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrc3068","volume":"11","author":"BG Wilson","year":"2011","unstructured":"Wilson BG, Roberts CWM. SWI\/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11:481\u201392.","journal-title":"Nat Rev Cancer"},{"key":"7529_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","volume":"23","author":"HA Malone","year":"2024","unstructured":"Malone HA, Roberts CWM. Chromatin remodellers as therapeutic targets. Nat Rev Drug Discov. 2024;23:661\u201381.","journal-title":"Nat Rev Drug Discov"},{"key":"7529_CR43","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1126\/science.1177321","volume":"325","author":"D Ahel","year":"2009","unstructured":"Ahel D, Horejs\u00ed Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 2009;325:1240\u20133.","journal-title":"Science"},{"key":"7529_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41556-020-00624-3","volume":"23","author":"P Verma","year":"2021","unstructured":"Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, et al. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. Nat Cell Biol. 2021;23:160\u201371.","journal-title":"Nat Cell Biol"},{"key":"7529_CR45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.molcel.2017.11.019","volume":"68","author":"HR Singh","year":"2017","unstructured":"Singh HR, Nardozza AP, M\u00f6ller IR, Knobloch G, Kistemaker HAV, Hassler M, et al. A Poly-ADP-Ribose trigger releases the Auto-Inhibition of a chromatin remodeling oncogene. Mol Cell. 2017;68:860\u2013e8717.","journal-title":"Mol Cell"},{"key":"7529_CR46","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1172\/JCI40665","volume":"120","author":"L Chen","year":"2010","unstructured":"Chen L, Chan THM, Yuan Y-F, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010;120:1178\u201391.","journal-title":"J Clin Invest"},{"key":"7529_CR47","first-page":"1581","volume":"11","author":"W Wang","year":"2019","unstructured":"Wang W, Wu J, Fei X, Chen W, Li Y, Shen K, et al. CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer. Am J Transl Res. 2019;11:1581\u201392.","journal-title":"Am J Transl Res"},{"key":"7529_CR48","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1007\/s10620-017-4641-8","volume":"62","author":"C Liu","year":"2017","unstructured":"Liu C, Fu X, Zhong Z, Zhang J, Mou H, Wu Q, et al. CHD1L expression increases tumor progression and acts as a predictive biomarker for poor prognosis in pancreatic cancer. Dig Dis Sci. 2017;62:2376\u201385.","journal-title":"Dig Dis Sci"},{"key":"7529_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41419-019-1371-1","volume":"10","author":"Y Li","year":"2019","unstructured":"Li Y, He L-R, Gao Y, Zhou N-N, Liu Y, Zhou X-K, et al. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-\u03baB axis in human non-small-cell lung cancer. Cell Death Dis. 2019;10:99.","journal-title":"Cell Death Dis"},{"key":"7529_CR50","doi-asserted-by":"publisher","first-page":"116679","DOI":"10.1016\/j.lfs.2019.116679","volume":"232","author":"F Li","year":"2019","unstructured":"Li F, Zhang Z, Wang P, Wen P, Xu Q, Wang Y, et al. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by Inhibition of Glycolysis through PI3K\/Akt pathway. Life Sci. 2019;232:116679.","journal-title":"Life Sci"},{"key":"7529_CR51","doi-asserted-by":"publisher","first-page":"e0188320","DOI":"10.1371\/journal.pone.0188320","volume":"12","author":"M Tsuda","year":"2017","unstructured":"Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, et al. ALC1\/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. PLoS ONE. 2017;12:e0188320.","journal-title":"PLoS ONE"},{"key":"7529_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.molcel.2020.12.006","volume":"81","author":"G Hewitt","year":"2021","unstructured":"Hewitt G, Borel V, Segura-Bayona S, Takaki T, Ruis P, Bellelli R, et al. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. Mol Cell. 2021;81:767\u2013e78311.","journal-title":"Mol Cell"},{"key":"7529_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1541-7786.MCR-04-0163","volume":"3","author":"RL Lynch","year":"2005","unstructured":"Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res MCR. 2005;3:163\u20139.","journal-title":"Mol Cancer Res MCR"},{"key":"7529_CR54","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1016\/j.ymthe.2021.04.036","volume":"29","author":"Z Chu","year":"2021","unstructured":"Chu Z, Huo N, Zhu X, Liu H, Cong R, Ma L, et al. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through Inhibition of PGK1-mediated Warburg effect. Mol Ther J Am Soc Gene Ther. 2021;29:2737\u201353.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"7529_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2019.11.042","volume":"470","author":"C Liu","year":"2020","unstructured":"Liu C, Zhao Y, Wang J, Yang Y, Zhang Y, Qu X, et al. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2\/TR1 signaling pathway. Cancer Lett. 2020;470:29\u201342.","journal-title":"Cancer Lett"},{"key":"7529_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-017-0664-1","volume":"16","author":"Z Liang","year":"2017","unstructured":"Liang Z, Wang X, Xu X, Xie B, Ji A, Meng S, et al. MicroRNA-608 inhibits proliferation of bladder cancer via AKT\/FOXO3a signaling pathway. Mol Cancer. 2017;16:96.","journal-title":"Mol Cancer"},{"key":"7529_CR57","doi-asserted-by":"publisher","first-page":"e2111","DOI":"10.1038\/cddis.2015.403","volume":"7","author":"TP Das","year":"2016","unstructured":"Das TP, Suman S, Alatassi H, Ankem MK, Damodaran C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death Dis. 2016;7:e2111.","journal-title":"Cell Death Dis"},{"key":"7529_CR58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10495-013-0905-8","volume":"19","author":"K-J Won","year":"2014","unstructured":"Won K-J, Kim BK, Han G, Lee K, Jung Y-J, Kim H-M, et al. NSC126188 induces apoptosis of prostate cancer PC-3 cells through Inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription. Apoptosis Int J Program Cell Death. 2014;19:179\u201390.","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"7529_CR59","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/bjc.2017.293","volume":"117","author":"W Liu","year":"2017","unstructured":"Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, et al. SGK1 Inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer. 2017;117:1139\u201353.","journal-title":"Br J Cancer"},{"key":"7529_CR60","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","volume":"21","author":"MD Galsky","year":"2010","unstructured":"Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:2135\u201344.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7529_CR61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2018.03.013","volume":"658","author":"Q Feng","year":"2018","unstructured":"Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene. 2018;658:152\u20138.","journal-title":"Gene"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07529-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:05:37Z","timestamp":1767798337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7529"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07529-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7424447\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all methods were conducted in accordance with the relevant guidelines and regulations. All mice were housed at the Animal Center of Chongqing Medical University, and approval was obtained from the Animal Committee of the Institute of Zoology at Chongqing Medical University (reference number: IACUC-CQMU-2025-03112, \u201cMechanism of targeting CHD1L in prostate cancer\u201d). Patient samples were obtained from PCa patients after informed consent of sample use for research. The use of human samples was approved by the Medical Ethics Committees of The First Affiliated Hospital of Chongqing Medical University (reference number: 2025-406-01, \u201cMechanism of targeting CHD1L in prostate cancer\u201d).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this work, the authors used \u201cChatGPT\u201d to enhance language quality and readability. After using this tool\/service, the authors have reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"All patients involved in this study provided written informed consent for the use of their clinical data for research and publication purposes. The consent process included disclosure that their de\u2013identified data may be made publicly available online and in print following publication. No identifying information (such as name, initials, date of birth, or hospital number) has been included in this manuscript. The study protocol and consent procedures were reviewed and approved by the institutional ethics committee, and all efforts were made to ensure patient confidentiality and compliance with data protection regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}